Canaccord Genuity Upgrades Intra-Cellular Therapies (ITCI) to Buy
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $131.87 --0%
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
Canaccord Genuity analyst Sumant Kulkarni upgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Hold to Buy with a price target of $132.00.
For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.
Shares of Intra-Cellular Therapies closed at $128.25 yesterday.
You May Also Be Interested In
- Northland Upgrades Hyliion Holdings (HYLN) to Outperform 'on Improved Visibility to KARNO Commercialization'
- Citi Upgrades Suzuki Motor Corp (7269:JP) (SZKMY) to Buy
- Wolfe Research Upgrades Abbvie (ABBV) to Outperform
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
